BATON ROUGE, LA (KSLA) - Louisiana has joined a multi-state settlement over allegations that Mylan, the drug manufacturer of the EpiPen, knowingly overcharged taxpayers for the product.
According to the office of La. Attorney General Jeff Landry, Mylan will pay $465 million to the federal government and the states.
Louisiana will get a total of $6,922,152.05. Gen. Landry said that money will go towards the state's Medicaid program.
From July 29, 2010 to March 31, 2017, Mylan allegedly submitted false statements to the Centers for Medicare and Medicaid Services that incorrectly classified the EpiPen and EpiPen Jr as a "non-innovator multiple source drug", according to the office of La. Attorney General.
Mylan also did not report the best price to Centers for Medicare and Medicaid Services. As a result, Mylan submitted or caused false statements to be submitted and underpaid its EpiPen/EpiPen Jr. rebates to state Medicaid programs.